Literature DB >> 7607552

Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat CYP2B2 gene.

E Trottier1, A Belzil, C Stoltz, A Anderson.   

Abstract

Cytochrome P450 2B1, encoded by CYP2B1, and cytochrome P450 2B2, encoded by CYP2B2, are inducible in rat liver by phenobarbital (PB). We have used cultured adult rat hepatocytes to study molecular mechanisms regulating CYP2B1/CYP2B2 transcription. Northern blot analysis demonstrated that the endogenous CYP2B1/CYP2B2 genes were inducible by PB in such cultures. A PB-responsive element (PBRE) conferring PB inducibility on a reporter gene was identified in the CYP2B2 5'-flanking region. The PBRE was localized to a 163-bp Sau3AI fragment situated between 2155 and 2318 bp upstream from the CYP2B2 transcription start point (tsp). The PBRE also conferred PB responsiveness on an enhancerless heterologous promoter and was active in both orientations both upstream and downstream from the heterologous promoter; hence, it has the properties of a transcriptional enhancer. Gel-retardation assays showed that nuclear extracts of liver cells of untreated and PB-treated rats contained sequence-specific DNA-binding factors that interact with a PBRE-containing DNA fragment. These results may open the way to identifying one or more transcription factors mediating induction of CYP2B2 and CYP2B1 in rat liver.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607552     DOI: 10.1016/0378-1119(94)00916-g

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  26 in total

1.  Functional interactions between an atypical NF-kappaB site from the rat CYP2B1 promoter and the transcriptional repressor RBP-Jkappa/CBF1.

Authors:  S H Lee; X Wang; J DeJong
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

2.  Estrogen modulates transactivations of SXR-mediated liver X receptor response element and CAR-mediated phenobarbital response element in HepG2 cells.

Authors:  Gyesik Min
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

Review 3.  Regulation of cytochrome P450 (CYP) genes by nuclear receptors.

Authors:  P Honkakoski; M Negishi
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 4.  Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.

Authors:  Curtis J Omiecinski; John P Vanden Heuvel; Gary H Perdew; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2010-11-08       Impact factor: 4.849

Review 5.  Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor.

Authors:  Sergio C Chai; Wenwei Lin; Yongtao Li; Taosheng Chen
Journal:  Drug Discov Today       Date:  2019-02-04       Impact factor: 7.851

6.  The CYP2B2 phenobarbital response unit contains binding sites for hepatocyte nuclear factor 4, PBX-PREP1, the thyroid hormone receptor beta and the liver X receptor.

Authors:  Marie-Josée Beaudet; Marc Desrochers; Antoine Amaury Lachaud; Alan Anderson
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

Review 7.  Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.

Authors:  Maria Almira Correia; Peter R Sinclair; Francesco De Matteis
Journal:  Drug Metab Rev       Date:  2010-09-23       Impact factor: 4.518

Review 8.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 9.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

Review 10.  Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

Authors:  Hongbing Wang; Edward L LeCluyse
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.